Basal insulin supplementation in type 2 diabetes; refining the tactics

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) burden is increasing, with more young patients and longer survival with chronic hyperglycemia complications.
• Conventional T2DM treatments (lifestyle, oral agents) are often ineffectual for long-term glycemic control.
• Early insulin addition to oral therapy shows promise in improving glycemic control.

Purpose of the Study:

• To evaluate the clinical utility of once-daily insulin glargine as an adjunct to oral pharmacotherapy in T2DM.
• To assess the effectiveness of a treat-to-target strategy using insulin glargine for glycemic control.
• To determine if insulin glargine can help achieve and maintain target glycosylated hemoglobin (HbA1c) levels.

Main Methods:

• Review of 2 recent randomized, controlled trials.
• Implementation of a treat-to-target algorithm initiating basal insulin glargine.
• Assessment of glycosylated hemoglobin levels to evaluate glycemic control.

Main Results:

• Supplementing oral pharmacotherapy with once-daily insulin glargine effectively achieves and maintains target HbA1c levels (≤7%).
• A simple treat-to-target strategy using insulin glargine is translatable to general practice.
• Insulin glargine's flexible, once-daily dosing and smooth profile are associated with fewer nocturnal hypoglycemia episodes.

Conclusions:

• Early addition of basal insulin glargine is a safe and practical strategy for T2DM management.
• This approach transforms the treatment paradigm by offering improved glycemic control.
• The treat-to-target algorithm facilitates the adoption of early insulin therapy in routine clinical practice.